TAS 5315
Alternative Names: TAS-5315Latest Information Update: 28 Mar 2025
At a glance
- Originator Taiho Pharmaceutical
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis; Urticaria
- No development reported Systemic lupus erythematosus
Most Recent Events
- 24 Oct 2024 Pharmacodynamics data from a preclinical trial in Spontaneous urticaria presented at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2024) .
- 24 Oct 2024 Efficacy and safety data from a phase II clinical trial in Chronic spontaneous urticaria presented at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2024)
- 28 Jun 2022 Phase-II clinical trials in Urticaria (Treatment-resistant) in Japan (PO) (NCT05335499)